comparemela.com

Sonalee Agarwal News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Alnylam Pharmaceuticals, Inc : Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy

-Treatment with Cemdisiran Resulted in a Higher Proportion of Patients Achieving Clinically Meaningful Reductions in 24-Hour Urine Protein to Creatinine Ratio, as Compared to Patients on Placebo -

United kingdomChristine regan lindenboomJosh brodskySonalee agarwalRegeneron pharmaceuticalsAlnylam pharmaceuticals incExchange commissionAlnylam pharmaceuticalsProgram leader for the cemdisiranCemdisiran resultedHigher proportionHour urine proteinCreatinine ratioProteinuria reduction seenSecondary endpointsWas generally well tolerated

Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy

09.06.2022 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today topline results from the Phase 2 study of cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the complement pathway that is in development in collaboration with . Seite 1

Sonalee agarwalRegeneron pharmaceuticalsProgram leader for the cemdisiranAlnylam pharmaceuticals incAlnylam pharmaceuticalsVice presidentProgram leader

Alnylam Pharma Reports Positive Topline Results From Phase 2 Study Of Cemdisiran

WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals, Inc. (ALNY) reported topline results from the phase 2 study of cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the

United statesSonalee agarwalRegeneron pharmaceuticalsProgram leader for the cemdisiranAlnylam pharmaceuticals incVice presidentProgram leader

vimarsana © 2020. All Rights Reserved.